
1. science. 2018 jan 12;359(6372):191-199. doi: 10.1126/science.aan4472.

mapping malaria parasite druggable genome using vitro evolution and
chemogenomics.

cowell an(1), istvan es(2), lukens ak(3)(4), gomez-lorenzo mg(5), vanaerschot
m(6), sakata-kato t(3), flannery el(1), magistrado p(3), owen e(7), abraham m(1),
lamonte g(1), painter hj(7), williams rm(1), franco v(5), linares m(5), arriaga
i(5), bopp s(3), corey vc(1), gnädig nf(6), coburn-flynn o(6), reimer c(1), gupta
p(1), murithi jm(6), moura pa(6), fuchs o(1), sasaki e(1), kim sw(1), teng ch(1),
wang lt(1), akidil a(8), adjalley s(8), willis pa(9), siegel d(10), tanaseichuk
o(11), zhong y(11), zhou y(11), llinás m(7), ottilie s(1), gamo fj(5), lee
mcs(6)(8), goldberg de(2), fidock da(6)(12), wirth df(3)(4), winzeler ea(13)(10).

author information: 
(1)school medicine, university california san diego (ucsd), 9500 gilman
drive, la jolla, ca 92093, usa.
(2)departments medicine molecular microbiology, washington university
school medicine, st. louis, mo 63110, usa.
(3)department immunology infectious disease, harvard t.h. chan school of
public health, 665 huntington avenue, boston, 02115, usa.
(4)infectious disease program, broad institute, 415 main street, cambridge,
ma 02142, usa.
(5)tres cantos medicines development campus, malaria discovery performance unit, 
glaxosmithkline, severo ochoa 2, tres cantos 28760, madrid, spain.
(6)department microbiology immunology, columbia university college of
physicians surgeons, new york, ny 10032, usa.
(7)department biochemistry molecular biology, pennsylvania state
university, university park, pa 16802, usa.
(8)malaria programme, wellcome sanger institute, wellcome genome campus, hinxton,
cambridgeshire cb10 1sa, uk.
(9)medicines malaria venture, post office box 1826, 20 route de pre-bois,
1215 geneva 15, switzerland.
(10)skaggs school pharmacy pharmaceutical sciences, ucsd, 9500 gilman
drive, la jolla, ca 92093, usa.
(11)genomics institute novartis research foundation, 10675 john j hopkins 
drive, san diego, ca 92121, usa.
(12)division infectious diseases, columbia university college physicians
and surgeons, new york, ny 10032, usa.
(13)school medicine, university california san diego (ucsd), 9500 gilman
drive, la jolla, ca 92093, usa. ewinzeler@ucsd.edu.

comment in
    science. 2018 jan 12;359(6372):159-160.
    microbiol insights. 2018 nov 27;11:1178636118808529.

chemogenetic characterization vitro evolution combined with
whole-genome analysis identify antimalarial drug targets drug-resistance 
genes. performed genome analysis 262 plasmodium falciparum parasites
resistant 37 diverse compounds. found 159 gene amplifications 148
nonsynonymous changes 83 genes associated drug-resistance acquisition,
where gene amplifications contributed one-third resistance acquisition
events. beyond confirming previously identified multidrug-resistance mechanisms, 
we discovered hitherto unrecognized drug target-inhibitor pairs, including
thymidylate synthase benzoquinazolinone, farnesyltransferase a
pyrimidinedione, dipeptidylpeptidase arylurea. exploration of
the p. falciparum resistome druggable genome likely guide drug discovery
and structural biology efforts, also advancing understanding of
resistance mechanisms available malaria parasite.

copyright © 2018 authors, rights reserved; exclusive licensee american
association advancement science. claim original u.s. government 
works.

doi: 10.1126/science.aan4472 
pmcid: pmc5925756
pmid: 29326268  [indexed medline]

